Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
paclitaxel + carboplatin + topotecan + filgrastim
- Development stage
- Unknown
- Lead developer
- SWOG Cancer Research Network
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Intravenous, Subcutaneous
01
Overview
This combination chemotherapy regimen was evaluated in the SWOG Cancer Research Network trial S9914 for the treatment of previously untreated extensive-stage small cell lung cancer (SCLC). The regimen consists of three active cytotoxic agents: **paclitaxel**, a microtubule-stabilizing agent that prevents mitotic spindle breakdown; **carboplatin**, a platinum-based agent that induces DNA cross-linking to inhibit replication; and **topotecan**, a topoisomerase I inhibitor that causes lethal DNA strand breaks. To mitigate the severe myelosuppression associated with this intensive triplet combination, **filgrastim** (granulocyte colony-stimulating factor, G-CSF) is administered as supportive care to stimulate the production of neutrophils. The Phase II study aimed to determine if this multi-targeted approach could improve outcomes in extensive-stage SCLC compared to standard doublet therapies.
- Other names
- Paclitaxel, Carboplatin, Topotecan, and G-CSFS9914 regimenS-9914 regimenS 9914 regimen
02
Targets
DNACSF3R (Granulocyte colony-stimulating factor receptor)TOP1 (DNA Topoisomerase I)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on paclitaxel + carboplatin + topotecan + filgrastim.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on paclitaxel + carboplatin + topotecan + filgrastim.